Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India
Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Biological DMARDs, also referred to as “biologics,” rapidly retard progression of the joint damage seen in RA. Rituximab is a well-established biologic for the ma...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=3;spage=311;epage=321;aulast=Talari |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542967482548224 |
|---|---|
| author | Keerthi Talari Vinod Ravindran Pradip Kumar Pravin Patil Sarath Chandra Mouli Syamasis Bandyopadhyay Balebail G Dharmanand Abhrajit Ray Shankaralingam Rajeshwari Sanjiv N Amin Jyotsna Oak Ved Chaturvedi Anand N Malaviya Sukumar Mukherjee |
| author_facet | Keerthi Talari Vinod Ravindran Pradip Kumar Pravin Patil Sarath Chandra Mouli Syamasis Bandyopadhyay Balebail G Dharmanand Abhrajit Ray Shankaralingam Rajeshwari Sanjiv N Amin Jyotsna Oak Ved Chaturvedi Anand N Malaviya Sukumar Mukherjee |
| author_sort | Keerthi Talari |
| collection | DOAJ |
| description | Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Biological DMARDs, also referred to as “biologics,” rapidly retard progression of the joint damage seen in RA. Rituximab is a well-established biologic for the management of RA with several biosimilar versions available. This document presents the consensus statements on the usage of rituximab for the management of RA developed by a group of 14 experienced rheumatologists from India. This expert panel identified areas of interests, collated and summarized relevant literature, developed, debated and refined and revised the statements which were voted upon at relevant stages. Subsequently, a wider consultative process including voting on the draft statements involved 18 more rheumatologists from across India. The approved final version has 28 consensus statements related to the following seven areas of rituximab therapy in RA, namely, contraindication, pretreatment screening, treatment schedule, evaluation of response, safety, and research agenda for future. It is envisaged that these consensus statements would help in optimizing the usage of rituximab in RA not only in India but also in other countries and benefit all stakeholders. |
| format | Article |
| id | doaj-art-8afbed8558ee4037a7ddc3fa0f34c61f |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-8afbed8558ee4037a7ddc3fa0f34c61f2025-02-03T12:03:05ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012021-01-0116331132110.4103/injr.injr_69_21Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in IndiaKeerthi TalariVinod RavindranPradip KumarPravin PatilSarath Chandra MouliSyamasis BandyopadhyayBalebail G DharmanandAbhrajit RayShankaralingam RajeshwariSanjiv N AminJyotsna OakVed ChaturvediAnand N MalaviyaSukumar MukherjeePharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Biological DMARDs, also referred to as “biologics,” rapidly retard progression of the joint damage seen in RA. Rituximab is a well-established biologic for the management of RA with several biosimilar versions available. This document presents the consensus statements on the usage of rituximab for the management of RA developed by a group of 14 experienced rheumatologists from India. This expert panel identified areas of interests, collated and summarized relevant literature, developed, debated and refined and revised the statements which were voted upon at relevant stages. Subsequently, a wider consultative process including voting on the draft statements involved 18 more rheumatologists from across India. The approved final version has 28 consensus statements related to the following seven areas of rituximab therapy in RA, namely, contraindication, pretreatment screening, treatment schedule, evaluation of response, safety, and research agenda for future. It is envisaged that these consensus statements would help in optimizing the usage of rituximab in RA not only in India but also in other countries and benefit all stakeholders.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=3;spage=311;epage=321;aulast=Talarib cell depletion therapybiologicalbiosimilardisease-modifying antirheumatic drugsrheumatoid arthritisrituximab |
| spellingShingle | Keerthi Talari Vinod Ravindran Pradip Kumar Pravin Patil Sarath Chandra Mouli Syamasis Bandyopadhyay Balebail G Dharmanand Abhrajit Ray Shankaralingam Rajeshwari Sanjiv N Amin Jyotsna Oak Ved Chaturvedi Anand N Malaviya Sukumar Mukherjee Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India Indian Journal of Rheumatology b cell depletion therapy biological biosimilar disease-modifying antirheumatic drugs rheumatoid arthritis rituximab |
| title | Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India |
| title_full | Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India |
| title_fullStr | Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India |
| title_full_unstemmed | Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India |
| title_short | Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India |
| title_sort | expert panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in india |
| topic | b cell depletion therapy biological biosimilar disease-modifying antirheumatic drugs rheumatoid arthritis rituximab |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=3;spage=311;epage=321;aulast=Talari |
| work_keys_str_mv | AT keerthitalari expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT vinodravindran expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT pradipkumar expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT pravinpatil expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT sarathchandramouli expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT syamasisbandyopadhyay expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT balebailgdharmanand expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT abhrajitray expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT shankaralingamrajeshwari expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT sanjivnamin expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT jyotsnaoak expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT vedchaturvedi expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT anandnmalaviya expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia AT sukumarmukherjee expertpanelconsensusstatementsontheoptimalusageofrituximabforthemanagementofrheumatoidarthritisinindia |